Literature DB >> 6976414

In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.

H Ozer, J W Cowens, M Colvin, A Nussbaum-Blumenson, D Sheedy.   

Abstract

The alkylating agent cyclophosphamide may suppress or enhance immune responses in vivo but is inactive in vitro unless metabolized by microsomal enzyme activation. 4-hydroperoxycyclophosphamide (4-HC) is a synthetic compound that is spontaneously converted in aqueous solution to the active metabolites. In this report, we examined the in vitro sensitivity of functional human T cell subsets to 4-HC in a polyclonal B cell differentiation assay and in the generation of mitogen-induced suppressor cells for effector B cell function. Con A-induced T suppression of B cell differentiation is completely abrogated by a 1-h pretreatment of T cells at very low concentrations of between 10(-2) and 20 nmol/ml, whereas inducer T cell function is sensitive only to concentrations in greater than 40 nmol/ml. The effects of 4-HC on suppressor T cells appear to occur at concentrations that do not result in DNA cross-linking or decreased blastogenesis. Con A-induced T suppressors are generated from within the OKT4+, OKT8- subset and are sensitive to low-dose 4-HC only before activation, whereas differentiated suppressor cells are resistant to concentrations in greater than 80 nmol/ml. Low-dose 4-HC pretreatment of the B cell population results in abrogation of immunoglobulin secretion when treated B cells are cocultured with unfractionated T cells, however, this effect is completely reversible if pretreated B cells are cocultured with T cells devoid of suppressor activity. These results demonstrate that human presuppressor cells for B-effector function differentiate in response to Con A from the OKT4+, OKT8- subset and are exquisitely sensitive to low concentrations of CYP whereas mature suppressor and inducer functions are resistant to all but very high concentrations in vitro. The differential sensitivity of functional T and B cell subsets to 4-HC in vitro can be a very useful probe in dissecting immunoregulatory interactions with man.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6976414      PMCID: PMC2186561          DOI: 10.1084/jem.155.1.276

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Regulation of the immune response. I. Suppression of delayed-type hypersensitivity by T cells from mice expressing humoral immunity.

Authors:  I A Ramshaw; P A Bretscher; C R Parish
Journal:  Eur J Immunol       Date:  1976-10       Impact factor: 5.532

2.  Induction of autoreactive T lymphocytes and their suppressor cells by cyclophosphamide.

Authors:  J L'age-Stehr; T Diamanstein
Journal:  Nature       Date:  1978-02-16       Impact factor: 49.962

3.  Regulation of cellular and humoral immune responses by T-cell subclasses.

Authors:  H Cantor; E A Boyse
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1977

4.  Regulation of the immune response. II. Repressor T cells in cyclophosphamide-induced tolerant mice.

Authors:  I A Ramshaw; P A Bretscher; C R Parish
Journal:  Eur J Immunol       Date:  1977-03       Impact factor: 5.532

5.  An improved rosetting assay for detection of human T lymphocytes.

Authors:  M E Kaplan; C Clark
Journal:  J Immunol Methods       Date:  1974-07       Impact factor: 2.303

6.  Chromic chloride: a coupling reagent for passive hemagglutination reactions.

Authors:  E R Gold; H H Fudenberg
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

7.  Radioimmunoassay for myeloma idiotype.

Authors:  S Gailani; B K Seon; A Nussbaum; E S Henderson; D Pressman
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

8.  Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide.

Authors:  P Debré; C Waltenbaugh; M E Dorf; B Benacerraf
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

9.  Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: absence in NZB mice.

Authors:  H Cantor; L McVay-Boudreau; J Hugenberger; K Naidorf; F W Shen; R K Gershon
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  33 in total

1.  Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.

Authors:  Bin Du; David J Waxman
Journal:  Cancer Lett       Date:  2019-11-22       Impact factor: 8.679

2.  Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice.

Authors:  J Limpens; R J Scheper
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors:  A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.

Authors:  A Lindemann; K Höffken; R E Schmidt; V Diehl; O Kloke; H Gamm; J Hayungs; W Oster; M Böhm; J E Kolitz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors:  Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

6.  In vitro selective effect of melphalan on human T-cell populations.

Authors:  S Ben-Efraim; L Komlos; J Notmann; J Hart; I Halbrecht
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

8.  In vitro effects of 4-hydroperoxycyclophosphamide on concanavalin A-induced human suppressor T cells.

Authors:  A Klajman; I Drucker; Y Manor; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

Authors:  M M Bartik; B A Baumgartel-Scofield; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 10.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.